We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Teladoc (TDOC - Free Report) closed at $30.07, marking a -1.15% move from the previous day. This move lagged the S&P 500's daily loss of 0.28%. Meanwhile, the Dow gained 0.39%, and the Nasdaq, a tech-heavy index, lost 6.73%.
Prior to today's trading, shares of the telehealth services provider had gained 22.02% over the past month. This has outpaced the Medical sector's loss of 2.73% and the S&P 500's gain of 2.48% in that time.
Teladoc will be looking to display strength as it nears its next earnings release, which is expected to be February 22, 2023. The company is expected to report EPS of -$0.27, down 285.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $633.71 million, up 14.34% from the prior-year quarter.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% higher within the past month. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Teladoc (TDOC - Free Report) closed at $30.07, marking a -1.15% move from the previous day. This move lagged the S&P 500's daily loss of 0.28%. Meanwhile, the Dow gained 0.39%, and the Nasdaq, a tech-heavy index, lost 6.73%.
Prior to today's trading, shares of the telehealth services provider had gained 22.02% over the past month. This has outpaced the Medical sector's loss of 2.73% and the S&P 500's gain of 2.48% in that time.
Teladoc will be looking to display strength as it nears its next earnings release, which is expected to be February 22, 2023. The company is expected to report EPS of -$0.27, down 285.71% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $633.71 million, up 14.34% from the prior-year quarter.
Any recent changes to analyst estimates for Teladoc should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% higher within the past month. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.